Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Avillion appoints Dr Anders Gersel Pedersen
AppointmentsAvillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
UniQure looking to raise US$200m
Latest NewsDutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
MS: Polpharma joins forces with Sandoz
Latest NewsPolpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Boehringer and Zealand to advance obesity drug
Latest NewsGerman pharma company Boehringer Ingelheim said the phase II trial for candidate drug BI456906 is expected to be initiated in late 2019 triggering a €20m milestone payment to Zealand Pharma A/S.
DPP3 triggers myocardial depression
Latest NewsResults presented at European Society of Cardiology Congress 2019 demonstrate a new disease mechanism predicting acute organ dysfunction in heart failure patients.
Pro-apoptotic protein blocks autoimmunity
Latest NewsA US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity.
Sequencing-ready DNA for fast Molecular Breeding results
Sponsored PublicationsBioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated efficient lysis reagents for e.g. different plant tissues. In contrast to common bind-wash-elute procedures, the process does not require washing steps. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
Immatics and Celgene enter $1.5bn deal
Latest NewsCelgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies.
Microbial feed company Unibio raises US$15m
Latest NewsDanish microbiology specialist Unibio International plc had completed a US$15m financing round led by West Hill Capital.
ADC Therapeutics and Freenome enter biomarker collaboration
Latest NewsUS company Freenome will use its multiomics platform to develop response biomarkers to ADC Therapeutics’ Phase II antibody drug conjugate (ADC) ADCT-402.